Factor V Gene Mutation Is a Risk Factor for Cerebral Venous Thrombosis

Summary

To evaluate the association between coagulation defects and cerebral venous thrombosis, a case-control study was conducted in 25 patients who had no autoimmune, neoplastic or infectious disease and 75 healthy individuals. There were no patients with deficiency of protein C or protein S. Four had resistance to activated protein C (APC) and one had APC resistance associated with antithrombin deficiency. APC resistance was investigated by DNA analysis, and diagnosed by the presence of a point mutation in the factor V gene, which predicts replacement of Arg⁵⁰⁶ with Gin at one of the two APC cleavage sites in activated factor V. The prevalence of APC resistance was 20% in patients and 2.7% in controls. This difference was statistically significant (p = 0.01) and the odds ratio was 9.1. A circumstantial factor predisposing to cerebral venous thrombosis (such as oral contraceptive intake, pregnancy, puerperium, trauma or prolonged immobilization) was reported in 72% of cases. In conclusion, APC resistance is the most frequent coagulation abnormality associated with cerebral venous thrombosis.

• References

• 1 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 3869-3880
• 2 Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, de Ron-de H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 3 Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
• 4 Buonanno FS, Moody DM, Ball MR, Laster DW. Computed cranial tomography findings in cerebral sinovenous occlusion. J Comput Assist Tomogr 1978; 2: 281-290
• 5 Frezzato M, Tosetto A, Rodeghiero F. Validation of a questionnaire for the diagnosis of venous thromboembolism. Br J Haematol 1994; 87: 79
• 6 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnositc criteria. Thromb Haemost 1994; 72: 880-886
• 7 Mannucci PM, Tripodi A. Laboratory screening of inherited thrombophilic syndroms. Thromb Haemost 1987; 57: 247-251
• 8 Feinstein DI. Lupus anticoagulant, anticardiolipin antibodies, fetal loss and systemic lupus erythematosus. Blood 1992; 80: 859-862
• 9 Enevoldson TP, Ross Russel RW. Cerebral venous thrombosis: new causes for an old syndrome; Quart. J Med 1990; 77: 1255-1275
• 10 Heistinger M, Rumpl E, Illiasch H, Turck H, Kyrle PA, Lechner K, Pabinger I. Cerebral sinus thrombosis in a patient with hereditary protein S deficiency: case report and review of the literature. Ann Hematol 1992; 64: 105-109
• 11 Ameri A, Bousser MG. Cerebral venous thrombosis. In: Cerebral ischemia: treatment and prevention Barret HJM, Machinski UC. eds Neurol Clin; 1992: 87-111
• 12 Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis. A review of 38 cases. Stroke 1985; 16: 199-213
• 13 Fairbum B. Intracranial venous thrombosis complicating oral contraception: treatment by anticoagulant drugs. Br Med J 1973; 2: 647
• 14 Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597-600